Using QPOP to Predict Treatment for Sarcomas and Melanomas

Condition(s) studied

Study summary

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.

Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.

Eligibility

Primary outcome measure(s)

• Percentage of patients with successful model generation for each tumour subtype. — 8 years.
  Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.
• Rates of radiological response from QPOP-directed treatment regimens. — 8 years.
  Complete and partial clinical response and stable disease.
• Survival outcomes from QPOP-directed treatment regimens. — 8 years.
  Overall survival, progression-free survival.

Trial sites (1)

More National Cancer Centre, Singapore trials in Singapore

Other trials for the same condition